Alchemab Therapeutics is pioneering the next generation of antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology. The company has developed a highly differentiated platform that harnesses the power of the immune system by analyzing patient antibody repertoires. Using well-defined patient samples, deep B cell sequencing, and computational analysis, Alchemab identifies convergent protective antibody responses among individuals who are susceptible but resilient to specific diseases, such as long-term cancer survivors. This unique approach enables the discovery of novel drug targets and therapeutics from antibodies shared across resilient populations.
